DYNAVAX WKN: A12EV9 ISIN: US2681582019 Kürzel: DVAX Forum: Aktien Thema: Hauptdiskussion

Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance https://www.prnewswire.com/news-releases/dynavax-reports-second-quarter-2023-financial-results-and-raises-full-year-revenue-guidance-301892494.html • Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increase • Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million • Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year

Ich hatte jetzt auch nichts anderes gefunden. Da war - vorhin jedenfalls - schon bissel Bewegung im 'Bio-Markt'. Das Volumen hier ist aber nicht besonders auffällig bisher.

Obwohl ich sehe gerade, dass generell die impfbuden heute zwischen 5 und 9 Prozent liegen... 🙄

@Summer.76, weißt du was wegen dem Anstieg heute? Good rumors vor der HV oder nur blinde Spekulation?

Dynavax misses on bottom line, but reaffirms 2023 guidance https://seekingalpha.com/news/3964031-dynavax-misses-bottom-line-reaafirms-2023-guidance • Although its Q1 2023 bottom line results came in below expectations, Dynavax Technologies (NASDAQ:DVAX) is trading flat in after-hours trading. • The boost could be the result of a sigh of relief from investors as the company maintained its 2023 financial guidance. This included projected HEPLISAV-B product revenue of between $165M and $185M. • In the quarter, Dynavax (DVAX) swung to a net loss ~$24.3M from net income of ~$32.9M in the year-ago period (-$0.19 per share diluted vs. $0.32). • The company was hurt in the quarter by a 59% decline in revenue to ~$46.9M. • Dynavax (DVAX) recorded no CpG 1018 adjuvant product revenue in Q1, compared to $91.5M in Q1 2022 as the company finished its obligations and product delivery under adjuvant COVID-19 collaboration agreements. • The company ended the quarter with cash, cash equivalents, and marketable securities of ~$652M, a ~4% increase from Dec. 31, 2022.

https://beststocks.com/dynavax-technologies-corp-reports-q1-financia/

nächste woche grosser impfkonferenz in washington💪🚀

https://www.prnewswire.com/news-releases/dynavax-announces-great-britain-marketing-authorization-for-heplisav-b-a-two-dose-adult-hepatitis-b-adjuvanted-vaccine-301757659.html Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine

Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance https://investors.dynavax.com/news-releases/news-release-details/dynavax-reports-fourth-quarter-and-full-year-2022-financial

Dynavax Announces Uplisting to the Nasdaq Global Select Market https://www.prnewswire.com/news-releases/dynavax-announces-uplisting-to-the-nasdaq-global-select-market-301734858.html ...today announced that effective as of market open today, January 31, 2023, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "DVAX".   ...

Wer weiß - ist der Adujant nicht noch in einigen Projekten ein Thema? Zusätzlich kann ja auch von anderen Unternehmen noch das Interesse daran für andere Impfstoffe steigen. Ich bin da vorsichtig optimistisch. Vielleicht nicht für kurzfristig, aber auf längere Sicht.

Befürchte, dass die Adjujanzumsätze rapide sinken, sollte der chinesische Impfstoff sich verspäten und biontech in China auch noch zugelassen werden. Dann wäre die gegenwärtige Marktkapitalisierung schon sehr hoch. Heplisavunsätze rechtfertigen (noch) nicht die 1,5 Mrd. Kann natürlich aber auch alles anders kommen

👍💪

Wird Zeit den EK wieder zu sehen....

Dynavax Reports Third Quarter 2022 Financial Results https://www.prnewswire.com/news-releases/dynavax-reports-third-quarter-2022-financial-results-301667261.html • Q3 2022 total revenue of $167.7 million, up 55% from $108.3 million for Q3 2021 • HEPLISAV-B® vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 • CpG 1018® adjuvant net product revenue of $126.3 million, up 50% from $84.3 million for Q3 2021 • Reiterates guidance for full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million  • On track for a second consecutive year of profitability